Anebulo Pharmaceuticals Inc (ANEB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 06/30
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,404 | 3,094 | 5,147 | 6,645 | 8,521 |
| Receivables | 245 | N/A | N/A | N/A | N/A |
| TOTAL | $1,963 | $3,508 | $5,371 | $6,816 | $9,048 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 505 | 565 | 625 | 685 | 0 |
| TOTAL | $505 | $565 | $625 | $685 | $N/A |
| Total Assets | $2,468 | $4,073 | $5,996 | $7,501 | $9,048 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 252 | 156 | 385 | 319 | 566 |
| Accrued Expenses | 317 | 104 | 625 | 695 | 151 |
| TOTAL | $569 | $261 | $1,010 | $1,014 | $717 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $569 | $261 | $1,010 | $1,014 | $717 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 25,933 | 25,933 | 25,933 | 25,933 | 25,633 |
| Common Shares | 26 | 26 | 26 | 26 | 26 |
| Retained earnings | -67,605 | -65,404 | -64,054 | -62,400 | -59,683 |
| TOTAL | $1,899 | $3,813 | $4,985 | $6,487 | $8,331 |
| Total Liabilities And Equity | $2,468 | $4,073 | $5,996 | $7,501 | $9,048 |